Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.

EBioMedicine - 1 Apr 2020

Shi Yuankai, Su Hang, Song Yongping, Jiang Wenqi, Sun Xiuhua, Qian Wenbin, Zhang Wei, Gao Yuhuan, Jin Zhengming, Zhou Jianfeng, Jin Chuan, Zou Liqun, Qiu Lugui, Li Wei, Yang Jianmin, Hou Ming, Xiong Yan, Zhou Hui, Du Xinhua, Wang Xiong, Peng Bo

Abstract excerpt

BACKGROUND: Blood-based biomarker such as circulating tumor DNA (ctDNA) has emerged as a promising tool for assessment of response to immunotherapy in solid tumors; But in hematological malignances, evidences are still lacking to support its clinical utility. In current study the feasibility of ctDNA for prediction and monitoring of response to anti-PD-1 therapy in Chinese patients with relapsed or refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to beta 2-Microglobulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to F-Box Proteins

Share to Hodgkin Disease

Share to Immune Checkpoint Inhibitors

Share to Jumonji Domain-Containing Histone Demethylases

Source

Open in PubMed Open full text

Identifiers

PMID: 32304999
DOI: 10.1016/j.ebiom.2020.102731
PMCID: PMC7186760

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.PMID 32304999Read ↗

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.Semantic proximity Read ↗

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.Semantic proximity Read ↗

Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.Semantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?Semantic proximity Read ↗

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNASemantic proximity Read ↗

Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphomaSemantic proximity Read ↗

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studySemantic proximity Read ↗

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patientsSemantic proximity Read ↗

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read ↗

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following chimeric antigen receptor T-cell therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.